Allergan, Mauna Kea Technologies & more — 5 updates on GI companies

Here are five updates on GI companies from the past week.

Allergan entered into a clinical trial agreement with Novartis to conduct a phase 2b study of Allergan's cenicriviroc and Novartis' lead FXR agonist in treating non-alcoholic steatohepatitis.

Allergan and Ironwood Pharmaceuticals, in partnership with the American Gastroenterological Association, launched a campaign focused on bowel health's importance. Talk show host Wendy Williams served as the summit's host.

Key Capital announced positive results for its liver cancer immunotherapy product hepcortespenlisimut-L. Key Capital proved the drug was safe and highly effective in treating 75 advanced liver cancer patients through a phase II study.

The FDA granted Bristol-Myers Squibb's biologics license application for Opdivo priority review status. The FDA's action date is Aug. 2.

Mauna Kea Technologies' confocal laser endomicroscopy platform Cellvizio matches histologic diagnostic findings in relation to major gastrointestinal diseases. Researchers measured Cellvizio's effectiveness against 399 prospective confocal laser endomicroscopy procedures between September 2013 and February 2015 at 12 participating centers.

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

ASC_GI_300x250

Featured Webinars

Featured Whitepapers

Featured Podcast